Showing results (581-590 of 1,191) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|November 21, 2018
On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapiesSteffen Unkel, Marjan Amiri, Norbert Benda, et al.Pharmaceutical Statistics|November 21, 2018
Phase II trial design with growth modulation index as the primary endpointJianrong Wu, Li Chen, Jing Wei, et al.Pharmaceutical Statistics|January 21, 2021
A Bayesian adaptive design for biosimilar trials with time-to-event endpointSheferaw Y Belay, Rongji Mu, Jin XuPharmaceutical Statistics|January 5, 2022
Return-to-baseline multiple imputation for missing values in clinical trialsYongming Qu, Biyue DaiPharmaceutical Statistics|March 25, 2021
Synergy evaluation of non-normalizable dose-response data: Generalization of combination index for the linear effect of drugsBranislav Novotný, Milan Nagy, Elena KurinPharmaceutical Statistics|January 11, 2012
Exact sample-size determination in testing non-inferiority under a simple crossover trialKung-Jong Lui, Kuang-Chao ChangPharmaceutical Statistics|January 26, 2012
Statistical analysis of data from dilution assays with censored correlated countsJorge Quiroz, Jeffrey R Wilson, Satrajit RoychoudhuryPharmaceutical Statistics|April 21, 2011
An inferential procedure for the probability of passing the USP dissolution testChieh Chiang, Chen-Fang Chen, Meng-Yang Huang, et al.Pharmaceutical Statistics|May 17, 2011
Another view on the analysis of cardiovascular morbidity/mortality trialsGerd K RosenkranzPharmaceutical Statistics|May 17, 2011
Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongationRobert Schall, Arne RingPageof 120